We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Preventive Surgeries Linked to Lower Risk of Breast Cancer

By HospiMedica International staff writers
Posted on 13 Sep 2010
Women with the inherited mutations of the breast cancer (BRCA) genes who had prophylactic mastectomy or the removal of the fallopian tubes and ovaries (salpingo-oophorectomy) were found to have a significantly lower risk of developing ovarian and breast cancers, according to a new study.

Researchers at the University of Pennsylvania School of Medicine (Philadelphia, USA) conducted a prospective, multicenter cohort study of 2,482 women with BRCA1 or BRCA2 mutations ascertained between 1974 and 2008, at 22 clinical and research genetics centers in Europe and North America, to assess the relationship of risk-reducing mastectomy or salpingo-oophorectomy with cancer outcomes. More...
The women were followed up until the end of 2009. The main outcome measures were breast and ovarian cancer risk, cancer-specific mortality, and overall mortality.

The results showed that no breast cancers were diagnosed in the 247 women with risk-reducing mastectomy, compared with 98 women of 1,372 diagnosed with breast cancer who did not have risk-reducing mastectomy. The researchers found no cases of ovarian cancer among women with the BRCA1 mutation after salpingo-oophorectomy, which was likewise linked to a lower risk of breast cancer in BRCA1 and BRCA2 mutation carriers without prior diagnosis of breast cancer. Additionally, undergoing salpingo-oophorectomy was associated with lower all-cause mortality (10% vs. 3%), breast cancer-specific mortality (6% vs. 2%), and ovarian cancer-specific mortality (3% vs. 0.4%). The study was published in the September 1, 2010, issue of the Journal of the American Medical Association (JAMA).

"Females who carry the inherited mutations of the BRCA1 or BRCA2 genes have a considerably higher chance of developing breast or ovarian cancer; there is a 56% lifetime risk of breast cancer and 84% lifetime risk of ovarian cancer,” concluded lead author Susan Domchek, M.D. "Compared with women who did not undergo risk-reducing salpingo-oophorectomy, undergoing salpingo-oophorectomy was associated with lower all-cause mortality, breast cancer-specific mortality, and ovarian cancer-specific mortality.”

Hundreds of BRCA mutations have been identified. Some of them cause increased risk of breast cancer, ovarian cancer, and other cancers. Instead of a 12% lifetime risk of breast cancer, women with high risk BRCA1 or BRCA2 gene mutations may have a risk of up to 60% risk of developing breast cancer. The increased risk of developing ovarian cancer is about 55% for women with high-risk BRCA1 mutations and about 25% for women with high-risk BRCA2 mutations. Women who are mutation carriers have cancer risk-management options that include risk-reducing salpingo-oophorectomy, risk-reducing mastectomy, annual cancer screening, and chemoprevention.

Related Links:

University of Pennsylvania School of Medicine




Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
IV Therapy Cart
Avalo I.V Therapy Cart
Mobile X-Ray System
K4W
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.